Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease

Effective, safe, and pharmacokinetically suitable drugs are urgently needed to curb the ongoing COVID-19 pandemic. The main protease or 3C-like protease (Mpro or 3CLpro) of SARS-CoV-2 is considered an important target to formulate potent drugs corresponding to its crucial role in virus replication a...

Full description

Bibliographic Details
Main Authors:	Hylemariam Mihiretie Mengist, Daniel Mekonnen, Ahmed Mohammed, Ronghua Shi, Tengchuan Jin
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-02-01
Series:	Frontiers in Pharmacology
Subjects:	potency safety pharmacokinetics inhibitors SARS-CoV-2 main protease
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2020.630500/full

id	doaj-b35aa105a0854052b83214a328fd33b7
record_format	Article
spelling	doaj-b35aa105a0854052b83214a328fd33b72021-02-01T10:03:25ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-02-011110.3389/fphar.2020.630500630500Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main ProteaseHylemariam Mihiretie Mengist0Hylemariam Mihiretie Mengist1Hylemariam Mihiretie Mengist2Daniel Mekonnen3Daniel Mekonnen4Ahmed Mohammed5Ronghua Shi6Tengchuan Jin7Tengchuan Jin8Tengchuan Jin9Department of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, ChinaHefei National Laboratory for Physical Sciences at Microscale, Division of Life Sciences and Medicine, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, University of Science and Technology of China, Hefei, ChinaDepartment of Medical Laboratory Science, College of Health Sciences, Debre Markos University, Debre Markos, EthiopiaHefei National Laboratory for Physical Sciences at Microscale, Division of Life Sciences and Medicine, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, University of Science and Technology of China, Hefei, ChinaDepartment of Medical Laboratory Science, College of Health Science and Medicine, Bahir Dar University, Bahir Dar, EthiopiaHefei National Laboratory for Physical Sciences at Microscale, Division of Life Sciences and Medicine, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, University of Science and Technology of China, Hefei, ChinaHefei National Laboratory for Physical Sciences at Microscale, Division of Life Sciences and Medicine, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, University of Science and Technology of China, Hefei, ChinaDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, ChinaHefei National Laboratory for Physical Sciences at Microscale, Division of Life Sciences and Medicine, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, University of Science and Technology of China, Hefei, ChinaCAS Center for Excellence in Molecular Cell Science, Chinese Academy of Science, Shanghai, ChinaEffective, safe, and pharmacokinetically suitable drugs are urgently needed to curb the ongoing COVID-19 pandemic. The main protease or 3C-like protease (Mpro or 3CLpro) of SARS-CoV-2 is considered an important target to formulate potent drugs corresponding to its crucial role in virus replication and maturation in addition to its relatively conserved active site. Promising baseline data on the potency and safety of drugs targeting SARS-CoV-2 Mpro are currently available. However, preclinical and clinical data on the pharmacokinetic profiles of these drugs are very limited. This review discusses the potency, safety, and pharmacokinetic profiles of potential inhibitors of SARS-CoV-2 Mpro and forward directions on the development of future studies focusing on COVID-19 therapeutics.https://www.frontiersin.org/articles/10.3389/fphar.2020.630500/fullpotencysafetypharmacokineticsinhibitorsSARS-CoV-2main protease
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Hylemariam Mihiretie Mengist Hylemariam Mihiretie Mengist Hylemariam Mihiretie Mengist Daniel Mekonnen Daniel Mekonnen Ahmed Mohammed Ronghua Shi Tengchuan Jin Tengchuan Jin Tengchuan Jin
spellingShingle	Hylemariam Mihiretie Mengist Hylemariam Mihiretie Mengist Hylemariam Mihiretie Mengist Daniel Mekonnen Daniel Mekonnen Ahmed Mohammed Ronghua Shi Tengchuan Jin Tengchuan Jin Tengchuan Jin Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease Frontiers in Pharmacology potency safety pharmacokinetics inhibitors SARS-CoV-2 main protease
author_facet	Hylemariam Mihiretie Mengist Hylemariam Mihiretie Mengist Hylemariam Mihiretie Mengist Daniel Mekonnen Daniel Mekonnen Ahmed Mohammed Ronghua Shi Tengchuan Jin Tengchuan Jin Tengchuan Jin
author_sort	Hylemariam Mihiretie Mengist
title	Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease
title_short	Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease
title_full	Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease
title_fullStr	Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease
title_full_unstemmed	Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease
title_sort	potency, safety, and pharmacokinetic profiles of potential inhibitors targeting sars-cov-2 main protease
publisher	Frontiers Media S.A.
series	Frontiers in Pharmacology
issn	1663-9812
publishDate	2021-02-01
description	Effective, safe, and pharmacokinetically suitable drugs are urgently needed to curb the ongoing COVID-19 pandemic. The main protease or 3C-like protease (Mpro or 3CLpro) of SARS-CoV-2 is considered an important target to formulate potent drugs corresponding to its crucial role in virus replication and maturation in addition to its relatively conserved active site. Promising baseline data on the potency and safety of drugs targeting SARS-CoV-2 Mpro are currently available. However, preclinical and clinical data on the pharmacokinetic profiles of these drugs are very limited. This review discusses the potency, safety, and pharmacokinetic profiles of potential inhibitors of SARS-CoV-2 Mpro and forward directions on the development of future studies focusing on COVID-19 therapeutics.
topic	potency safety pharmacokinetics inhibitors SARS-CoV-2 main protease
url	https://www.frontiersin.org/articles/10.3389/fphar.2020.630500/full
work_keys_str_mv	AT hylemariammihiretiemengist potencysafetyandpharmacokineticprofilesofpotentialinhibitorstargetingsarscov2mainprotease AT hylemariammihiretiemengist potencysafetyandpharmacokineticprofilesofpotentialinhibitorstargetingsarscov2mainprotease AT hylemariammihiretiemengist potencysafetyandpharmacokineticprofilesofpotentialinhibitorstargetingsarscov2mainprotease AT danielmekonnen potencysafetyandpharmacokineticprofilesofpotentialinhibitorstargetingsarscov2mainprotease AT danielmekonnen potencysafetyandpharmacokineticprofilesofpotentialinhibitorstargetingsarscov2mainprotease AT ahmedmohammed potencysafetyandpharmacokineticprofilesofpotentialinhibitorstargetingsarscov2mainprotease AT ronghuashi potencysafetyandpharmacokineticprofilesofpotentialinhibitorstargetingsarscov2mainprotease AT tengchuanjin potencysafetyandpharmacokineticprofilesofpotentialinhibitorstargetingsarscov2mainprotease AT tengchuanjin potencysafetyandpharmacokineticprofilesofpotentialinhibitorstargetingsarscov2mainprotease AT tengchuanjin potencysafetyandpharmacokineticprofilesofpotentialinhibitorstargetingsarscov2mainprotease
_version_	1724315526798245888

Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease

Similar Items